Followers | 833 |
Posts | 119916 |
Boards Moderated | 17 |
Alias Born | 09/05/2002 |
Tuesday, January 16, 2018 4:39:44 PM
[Updated for disclosures concurrent with JPM conference.]
FoB program
• Timing unknown: M923 (Humira FoB) commercial partnership or out-license.
• 1H18: Start phase-3 trial for M710 (Eylea FoB).
• mid 2018: Report reason for inability of M834 (Orencia FoB) to meet its phase-1 pharmacokinetic endpoint; start phase-1 do-over, if necessary.
Proprietary autoimmune program
• 1H18: Start phase-1 trial of M230, which is partnered with CSL (#msg-127656306).
• 2018 Start phase-1 trial of M254, a hyper-sialylated IVIG.
Copaxone program
• 2H18: Anticipated FDA approval of NVS/MNTA’s 40mg-Copaxone ANDA. (On 2/17/17, MNTA reported that the ANDA approval was held up due to an FDA compliance issue at PFE’s fill/finish facility at McPherson, KS, which NVS/MNTA are using for Copaxone. Approval of the ANDA can’t happen until PFE fixes the compliance issue at this site.)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM